Pulmonary Hypertension Increases ARDS Mortality Risk Pulmonary Hypertension Increases ARDS Mortality Risk
Coexisting pulmonary hypertension may be a marker for disease severity among patients with acute respiratory distress syndrome.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 17, 2023 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news
'Surprising' Contribution of Pulmonary Hypertension to ARDS Outcomes
(MedPage Today) -- HONOLULU -- As suspected, patients with acute respiratory distress syndrome (ARDS) had particularly bad outcomes if they had coexisting pulmonary hypertension (PH), an analysis of the National Inpatient Sample showed.
Compared... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - October 12, 2023 Category: Urology & Nephrology Source Type: news
Value of Echocardiography in Pulmonary Hypertension Value of Echocardiography in Pulmonary Hypertension
Could echocardiography have a role in the diagnosis and prognosis of pulmonary hypertension?BMC Pulmonary Medicine (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 5, 2023 Category: Transplant Surgery Tags: Pulmonary Medicine Journal Article Source Type: news
ILD Plus PH Equals Poor Outcomes in Systemic Sclerosis ILD Plus PH Equals Poor Outcomes in Systemic Sclerosis
Patients with systemic sclerosis who have both interstitial lung disease and pulmonary hypertension have worse survival than those without both conditions, based on data from more than 3000 individuals.MDedge News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - August 30, 2023 Category: Rheumatology Tags: Rheumatology News Source Type: news
How much radiation do children with pulmonary hypertension receive?
Children with pulmonary hypertension can receive up to an average of 8.5 mS...Read more on AuntMinnie.comRelated Reading:
Use of sedation techniques lessens slightly in pediatric CT, MRI
ECR: Is chest CT indicated for children with suspected COVID-19?
'Pop-up' alert boosts appropriate pediatric CT use in the ED
ACR publishes pediatric CT radiation dose benchmarks
Academic pediatric facilities have lower CT radiation dose (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 28, 2023 Category: Radiology Source Type: news
PCCT produces diagnostic CTPA images for PE at low contrast dose
Photon-counting CT (PCCT) produces diagnostic CT pulmonary angiography (CTPA...Read more on AuntMinnie.comRelated Reading:
AI-assisted tool cuts CTPA report turnaround, exam wait times
Texture analysis of CTPA may improve PE assessment
Automated volumetry on CTPA can spot pulmonary hypertension
AI can augment radiologists for detecting PE on CTPA scans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 30, 2023 Category: Radiology Source Type: news
Liquidia signs $200M+ deal to expand drug portfolio
Liquidia is growing its portfolio for pulmonary hypertension treatments through a deal potentially worth well above $200M. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 29, 2023 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
Liquidia inks $200M+ deal to expand drug portfolio
Liquidia is growing its portfolio for pulmonary hypertension treatments through a deal potentially worth well above $200M. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 29, 2023 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
TREMFYA ® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
SPRING HOUSE, PENNSYLVANIA, May 31, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment with TREMFYA® (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR).[1] In a separate post-hoc analysis of the Phase 3 DISCOVER-1 and DISCOVER-2b clinical trial findings, TREMFYA was shown to be associated with prompt and su...
Source: Johnson and Johnson - May 31, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
RARITAN, NJ, May 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of an investigational single tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) in adult patients with WHO functional class (FC) II-III.[1] The application is based on positive data from the Phase 3 A DUE study, which met its primary endpoint and demonstrated that M/T STCT si...
Source: Johnson and Johnson - May 30, 2023 Category: Pharmaceuticals Source Type: news
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
What Causes Pulmonary Edema?
Discussion
Pulmonary edema is a potentially life threatening condition due to accumulation of excess fluid in the alveolar spaces and walls of the lung.
Patients show increased respiratory effort or distress (e.g. tachypnea, dyspnea or difficulty talking, use of excessory muscles, nasal flaring, tracheal tugging, etc.) and clinicians should beware signs of tiring (e.g. bradypnea and decreased effort) as the patient may be failing. Patients may have rales or rhonchi on pulmonary examination, and pallor or color changes may be noted. Blood gas analysis shows evidence of hypoxemia and often hypercapnia depending on the severi...
Source: PediatricEducation.org - May 15, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
First Phase 3 TREMFYA ® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, May 9, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.1,c The data show statistically significant and clinically meaningful improvements across symptomatic and histo-endoscopic outcome measures.1 Safety data were also consistent with the known safety profile of TREMFYA in ...
Source: Johnson and Johnson - May 9, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
HORSHAM, Pa., May 2, 2023 – Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. These investigational CD20-directed autologous CAR-Ts have demonstrated promising overall and complete response rates in Phase 1 studies in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) in China, with the m...
Source: Johnson and Johnson - May 2, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
